RAS Mutation Screening Panel
Cat Number: RAS-RT50
The RAS Mutation Screening Panel is a polymerase chain reaction (PCR)-based assay that uses allele-specific primers in a multiplex reaction to identify the presence of the mutations in a total of 8 reactions per sample.
RAS Mutations and Cancer
KRAS and NRAS are members of the RAS family of GTPases that play a central role in the MAPK signaling pathway. Activating mutations in exon 2 (codon 12/13), exon 3 (codon 59/61), and exon 4 (codon 117/146) have been found in various cancers, including metastatic colorectal cancer. Recent clinical studies using anti-EGFR targeted therapies of patients diagnosed with colorectal cancer have demonstrated that tumors possessing KRAS and NRAS mutations are less likely to respond to such therapies than those without mutations (Clin Cancer Res 2013;19:1902-1912).
Video http://entrogen.com/web3/videos/ras.htm
Intended Use:
USA:
For research use only (RUO). Not for use in diagnostic procedures.
Europe:
For research (RUO) and diagnostic (CE-IVD) purposes.